Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

We all know that we age as time goes by, what may come as a surprise is that according to new studies, each of our organs ...

After Gene Hackman's death, which followed the death of his caregiver wife, Bruce Willis' wife Emma Heming speaks out about ...

This unexpected early warning sign relates to a change in sensory perception, specifically your sense of smell. A declining ...

The US President has repeatedly vowed to seize the semi-autonomous Danish territory, where deposits of rare-earth minerals ...

ABU DHABI, 13th March, 2025 (WAM) - Cleveland Clinic Abu Dhabi, part of M42 group, has made significant contributions to the development of complex care in the region over the last 10 years, setting ...

Scientists at a technology company said Sunday they have created human embryos through cloning, drawing criticism from President Bush and lawmakers and raising new ethical questions. Advanced Cell ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...